Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects With Coronary Artery Disease

NCT00706849 is registered in ClinicalTrials.gov with Kastle Therapeutics, LLC as lead sponsor.

NCT NCT00706849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00706849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects With Coronary Artery Disease
Lead sponsor
Kastle Therapeutics, LLC
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2008
Completion date
May 31, 2010
Enrollment
124 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, heterozygous familial hypercholesterolemia